• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A blood coagulation Factor IX preparation is separated from plasma by selective adsorption of Factors II, IX and X, to the substantial exclusion of Factors VII and VIII, with 0.025-0,1% by weight of a water-insoluble, crosslinked polyelectrolyte copolymer of ethylene and maleic anhydride containing pendant diloweralkylaminoloweralkyl functional groups.
    公开号:SU841572A3
    申请号:SU782639950
    申请日:1978-07-21
    公开日:1981-06-23
    发明作者:Жан Джозеф Делент Жак；Алэн Шэнфельд Ричард
    申请人:Монсанто Компани (Фирма)；
    IPC主号:
    专利说明:

     one . , The invention relates to medicine, namely to hematology.
    A method of obtaining protein blood components by adsorbing blood on cross-linked polyelectrolytes copolymers containing ethylene and maleic anhydride is known, followed by elution of the target product using a physiologically acceptable salt Lll.
    However, the known method does not allow to obtain a high purity drug. .
    The purpose of the invention is to increase the purity of the drug. The goal is achieved by the method of obtaining protein components of blood by adsorbing blood on cross-linked polyelectrolytes - copolymers containing ethylene and maleic anhydride, followed by elution of the target product with a physiologically acceptable salt, liquid blood plasma is subjected to, inter action at pH 7.5-8.5 with polyelectrolyte in the amount of 0.025-0.1% with the content of lateral di-alkyl-amino-lower. -alkyl functional groups.
    Moreover, the di-alkyl-amino lower functional group is dimethylaminopropyl.
    The method is carried out as follows.
    . The original plasma get in fresh frozen form. Before fractionation by polyelectrolyte copolymer
    the plasma is thawed by heating to 35 ° C. The corresponding polyelectrolyte copolymer is added to the plasma at a concentration of about 0.025-0.1%, preferably 0.035-0.05% at pH 7.5-8.5. The mixture is stirred for about 10 minutes,. at this time, the preparation containing factor IX is selectively adsorbed by the polyelectrolyte copolymer. The remaining liquid plasma contains factors II, IX, and X. Water-insoluble, transversely, the crosslinked polyelectrolyte copolymers contain ethylene and maleic anhydride with the content of lateral diminishing alkyl-amino lower alkyl groups.
    The main copolymer containing ethylene and maleic anhydride
    - (AMK), obtained by the interaction of ethylene and maleic anhydride in the npHcyTCTBjjH peroxide catalyst in an appropriate solvent. The copolymer preferably contains substantially equimolar amounts of ethylene and anhydride residues.
    The main copolymer of the AMK type can be reacted with a lower alkyl-amino-bis-lower alkyl-amine containing two primary amino groups to form a 5-linked cross-linked copolymer of the AMK type. side functionalized di-alkyl-amino-lower alkyl groups can be added to a cross-linked copolymer by reacting the di-alkyl-aminone-lower alkyl-amine with a portion of the total AMK anhydride groups.
    Preferably the poly-electrolyte copolymer is also converted to the hydrochloric acid salt.
    The preferred functional lower alkyl-amino-lower alkyl group is dimethylaminopropyl, the preferred crosslinking agent. Is methylimino-propylamine.
    Preferred polyethylene electrolyte.-copolymer is one that contains about 5 methylimino-propylamine crosslinking groups and about 90 side dimethylaminopropylamine functional groups per 100 units of maleic anhydride in an AMK-type polymer.
    Other crosslinking agents can be used, for example, divinylbenzene and ethylene diamine, as well as functional groups, for example, dimethylaminoethyl and diethylaminobutyl.
    After adsorption of factor IX, factor VIII, remaining in the plasma, can be further concentrated and improved by known methods. An adsorbed preparation based on factor IX is easily isolated by elution from a polyelectrolyte copolymer by washing with an aqueous solution of sodium chloride with a molarity of about 1-3. About 0.035% by weight of a polyelectrolyte copopimer containing about 5 methyliminobropropylamine cross-linking groups and. about 90 dimethylaminopropylamine functional groups per 100 units of maleic anhydride; in the AMK type copolymer, they are used for the selective adsorption of a preparation based on factor IX at pH 8.
    The adsorbed preparation based on the protein components of the blood is eluted from the polyelectrolyte copolymer by washing with 1.7 M-NaCl at pH B. The eluate is then dialyzed against 0.1 M NaCl during freezing and stored for storage.
    Example 1. A polyelectrolyte copolymer consisting of a reaction product of mainly equimolar portions of ethylene and maleic anhydride (AMK), cross-linked with methyliminobopropylamine (MIBPA), is reacted with dimethylaminopropylamine (DMAPA) to produce about 5 x1). and about 90 side groups of DMAPA per 100 units of | {ez of maleic anhydride in an AMK type copolymer with transferring then to hydrochloric acid salt. :
    1 liter of human ordinary plasma using a single molar ;; The sodium hydroxide is adjusted to pH 8 by adding then 0.35 g of the polyelectrolyte copolymer, after which the mixture is stirred for 20 minutes, filtered, and the filter 5 Pt is depleted as depleted factor IX
    plasma. The meal is washed with distilled water to remove protein extracted from the plasma.
    Q The polyelectrolyte copolymer can also be reacted with divinylbenzene 3 as a cross-linking agent and dimethyl-aminoethyl pamine as a supplier of functional groups. Ethylenediamine- and diethylaminobutylamine can also be used in the quantities mentioned.
    Then, a preparation based on factor IX. Containing factors II, is eluted from the polyelectrolyte copolymer. IX and X, washing with 25 ml of 1.7 M sodium chloride at pH 6, about (pH adjusted to this value with 0.1: M citric acid) for 20. The copolymer slurry is filtered, the filtrate is collected as the desired composition based on factor IX. In a series of seven repeated runs of fractionation of 1 liter each, using predlogae | oIo method, an average of 483 ± 48 units of protein components of factor IX per liter are obtained with a purity ratio of 178 ± 33.
    One, unit fact: | ora IX counts the amount. Of this factor in 1 ml of the mixed, usually whole plasma. we. The index of index number is calculated as the ratio of the total amount of protein in the initial plasma and the total amount of protein in the whole preparation containing factor IX multiplied by the ratio of edfchich factor IX target drug on: the basis of factor I X and units of factor I f in the original
    plasma ..
    Example -2. 0.4 g / ml of the polyelectrolyte copolymer of the composition of example 1 is used to admix ordinary human plasma for
    20 minutes at a pH of 7.4 to extract the preparation containing factor IX IX, similarly to the method of Example I1.
    The table shows the results of measurements of adsorption factors in terms of
    on the original plasma. i
    Facts
    Adsorption,%
    These results indicate a high selectivity with respect to the adsorption of factors II, .1X and X with the complete elimination of factors VII and VI and in terms of the corresponding amounts of these factors in the initial plasma.
    Example 3. According to the method described in Example 1, a copolymer containing ethylene and maleic anhydride (AMK) is cross-linked with methyliminobispropylamine (MIBPD) and then reacted with dibutylaminobutylamine (DBBL) instead of dimethylaminopropylamine (DMAP gives similar results.
    The proposed method allows to obtain a drug of high purity.
    权利要求:
    Claims (2)
    [1]
    1. A method of obtaining protein components of blood by adsorbing blood on cross-linked poly-electrolytes copolymers containing ethylene and
    0 maleic acid anhydride, followed by elution of the target product with a physiologically acceptable salt, characterized in that, p. purity enhancement
    5 of the drug, the liquid blood plasma is subjected to interaction at pH 7.5-8.5 with polyelectrolyte in an amount of from 0.025-0.1% with the content of lateral di-alkyl-amino-lower-alkyl0. functional groups.
    [2]
    2. The method according to claim 1, about tl and h. Yusch and with the fact that diznesha-alkyl-amino-lower functional group of dimethylaminopropyl.
    five
    Sources of information taken into account in the examination
    1. US patent No. 3455001, cl. 260-112, 1969.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU841572A3|1981-06-23|Method of preparing protein blood components
    US3925344A|1975-12-09|Plasma protein substitute
    Wang et al.1971|Unusual fragments in the subunit structure of concanavalin A
    Silvanovich et al.1991|Nucleotide sequence analysis of three cDNAs coding for Poa p IX isoallergens of Kentucky bluegrass pollen.
    EP1560590B1|2008-10-22|Synthetic complementary peptides and ophthalmologic uses thereof
    DE2717741C2|1990-10-25|
    GB2055868A|1981-03-11|Blood substitute containing hemoglobin
    Baseler et al.1983|Purification of haptoglobin and its effects on lymphocyte and alveolar macrophage responses
    SU1375116A3|1988-02-15|Method of blood coagulation
    PL99599B1|1978-07-31|THE METHOD OF OBTAINING EXTREMELY TOLERATED GAMMAGLOBULIN
    CN108752468A|2018-11-06|Wound spray
    SU1012786A3|1983-04-15|Method for preparing proteinaceous complex stimulating secretion of insulin
    US4097473A|1978-06-27|Production of serum albumin
    CA1266550A|1990-03-06|Polymer resins with amino acid containing pendantsfor sorption of bile pigments and bile acids
    JPH03127800A|1991-05-30|Tumor necrosis factor activity inhibitor
    ES420846A1|1976-06-16|Production of gamma globulin
    JPH0597897A|1993-04-20|Egg-shell membrane decomposed product
    Maurer et al.1974|Multigenic control of immune responses of inbred mice against the terpolymers poly | and poly | and linkage withH-2 haplotype
    EP0228404A1|1987-07-15|Pentapeptides with cell growth regulatory effects and a process for the preparation thereof.
    CH645880A5|1984-10-31|SYNTHETIC ANTIGENT ACTIVE POLYPEPTIDE, METHOD FOR THE PRODUCTION THEREOF, AND ANTIGEN AGENT AND POLYPTIDE CONTAINING IT, AND MEDICINAL PRODUCT.
    JP2824254B2|1998-11-11|Fibroblast growth substance
    EP0257084B1|1990-12-27|Use of a dipeptide with cell growth regulating effect for the preparation of a medicament
    EP1006125B1|2007-02-14|Goat epididymal forward motility protein
    CA1224778A|1987-07-28|Antitumor glycoprotein substance and preparationthereof
    EP0136093A2|1985-04-03|Anti-cancer factors
    同族专利:
    公开号 | 公开日
    AU517885B2|1981-09-03|
    MX5405E|1983-07-13|
    DE2861573D1|1982-03-11|
    CA1107649A|1981-08-25|
    RO75338A|1980-11-30|
    ES471857A1|1979-02-01|
    JPS6154008B2|1986-11-20|
    IT1097302B|1985-08-31|
    AT359645B|1980-11-25|
    ATA531778A|1980-04-15|
    EP0000651A1|1979-02-07|
    US4081432A|1978-03-28|
    JPS5426322A|1979-02-27|
    PT68337A|1978-08-01|
    IT7826005D0|1978-07-21|
    EP0000651B1|1982-01-27|
    IL55194D0|1978-09-29|
    HU180882B|1983-05-30|
    AU3824378A|1980-01-24|
    PT68337B|1994-02-25|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3554985A|1963-01-02|1971-01-12|Monsanto Co|Cross-linked copolymer polyelectrolytes based on alpha,beta-ethylenically unsaturated acids|
    US3717708A|1968-10-24|1973-02-20|Cutter Lab|Blood coagulation complex|
    US3555001A|1969-05-29|1971-01-12|Monsanto Co|Process for the fractionation of plasma and serum using water-insoluble polyelectrolytes containing diloweralkylaminoloweralkylimide groups|
    US3682881A|1970-10-02|1972-08-08|Baxter Laboratories Inc|Fractionation of plasma using glycine and polyethylene glycol|
    IL42254A|1973-05-13|1977-03-31|Yeda Res & Dev|Polymeric carrier for biologically active proteins and biologically active substances based on these|
    US3920625A|1973-06-19|1975-11-18|Kabi Ab|Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates|
    DE2534603C2|1975-08-02|1984-10-31|Basf Ag, 6700 Ludwigshafen|Process for the preparation of copolymers with N-dialkyl-N-amido groups|GB1603244A|1977-05-20|1981-11-18|Max Planck Gesellschaft|Medicaments for the suppression of pathological processes|
    ES471858A1|1977-07-25|1979-02-01|Monsanto Co|Non-activating polyelectrolytes and their use in a method for separation of blood coagulation factors.|
    FR2472390B1|1979-05-04|1983-07-08|Merieux Inst|
    SE448945B|1979-12-20|1987-03-30|Blombaeck E G B|PROCEDURE FOR CLEANING AND / OR CONCENTRATION OF THE FACTOR VIII COMPLEX|
    AT368883B|1980-07-22|1982-11-25|Immuno Ag|METHOD FOR PRODUCING A NEW HUMAN PROTEIN-BASED PREPARATION PROCESSING BLOOD|
    DE3045153A1|1980-11-29|1982-07-08|Behringwerke Ag, 3550 Marburg|METHOD FOR THE PRODUCTION OF BLOOD COagulation FACTORS AND THE PREPARATION OF FACTORS IX AND X THEREFORE PRODUCED|
    US4447416A|1982-04-28|1984-05-08|American National Red Cross|Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy|
    US4397841A|1982-06-28|1983-08-09|Monsanto Company|Production of blood coagulation factor VIII:C|
    US4382028A|1982-07-19|1983-05-03|Monsanto Company|Separation of plasma proteins from cell culture systems|
    US5055557A|1983-03-04|1991-10-08|Scripps Clinic & Research Foundation|Ultrapurification of factor IX and other vitamin K-dependent proteins|
    US5614500A|1983-03-04|1997-03-25|The Scripps Research Institute|Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography|
    US4786726A|1986-01-06|1988-11-22|Blood Systems, Inc.|Factor IX therapeutic blood product, means and methods of preparing same|
    DE3627762A1|1986-08-16|1988-02-18|Behringwerke Ag|METHOD FOR PRODUCING A LOW PROTHROMBINE PREPARATION VITAMIN K-DEPENDENT COagulation FACTORS, AND A SUBSTANCE AVAILABLE AFTER THIS|
    ZA877535B|1986-10-09|1988-04-11|F. Hoffmann-La Roche & Co. Aktiengesellschaft|Factor ix-peptides|
    CA2203759A1|1995-08-28|1997-03-06|Ryusuke Okamoto|Serum or plasma separating compositions|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/818,920|US4081432A|1977-07-25|1977-07-25|Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers|
    [返回顶部]